Physician profile
James E Beitzel
NPI 1912901851
$11,535.62
in general payments reported to CMS, 2019-2025
48 companies · $2,883 in 2025
The $2,883 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,007 · 2020: $352 · 2021: $454 · 2022: $989 · 2023: $2,234 · 2024: $2,616 · 2025: $2,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,733.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,973.87 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,000.30 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $966.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $860.90 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $823.04 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $597.84 | 2019-2025 | Jardiance, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $502.86 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $439.79 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $409.75 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.57 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $307.70 | 2021-2025 | Freestyle Libre 3 |
| Lundbeck LLC | $269.60 | 2023-2025 | Rexulti, Vyepti |
| Janssen Pharmaceuticals, INC | $240.42 | 2019-2023 | Xarelto, Spravato |
| Amgen INC. | $229.75 | 2019-2024 | Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $219.96 | 2021-2025 | Gvoke Hypopen |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Beitzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.